



**EVITRADE
Health
Systems
Corporation**

EVITRADE Health Systems Signs Letter of Intent to Obtain License Dealer Classification in Canada

VANCOUVER, BC, Friday June 22, 2018 – EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: AXHLF) (the “Company”) announces that it has signed a Letter of Intent to collaborate with West Coast Medical Solutions Ltd. (“WCMS”).

WCMS together with their partner Ecovita Packaging Ltd. (“Ecovita”) intend to undertake a project to apply to become a Licensed Dealer (LD) as issued by Health Canada for Class A precursors. The Company will focus on uses regarding medical cannabis, tetrahydrocannabinol (“THC”) and cannabidiol (CBD). Ecovita maintains a relationship with Medtrica Canada which is privately owned by one of the shareholders of WCMS. Medtrica holds a FDA and Health Canada MDEL (Medical Device Establishment License) and is an ISO13485 medical products manufacturer in British Columbia, Canada. Medtrica is also currently building a brand new 40,000 sq. ft. state of the art manufacturing, processing and packaging facility with an estimated completion date in October 2018.

Pursuant to provisions of the *Controlled Drugs and Substances Act* (CDSA) and the *Precursor Control Regulations* (PCR), receipt of the LD license holder permits the Company to possess, package, and transport or deliver cannabis within Canada in addition to importing and exporting.

“With the Company’s collaboration with WCMS to become a certified Licensed Dealer, we will be able to further our plans to develop and distribute medical grade products that can potentially solve a series of ailments that plague the human condition” said CK Cheung, CEO of Evitrade. *“This latest agreement provides the manufacturing capabilities and access to a fully accredited ISO13485 medical device manufacturing facility; which will greatly strengthen our overall biotech capabilities and provide a level of integration that will make us more competitive and efficient.”*

Management continues to strive to seek optimal business and commercialization strategies for the Company, including the recent finalization of a definitive agreement with Cantech Molecular Research Inc. This, with the continuing engagement of Haywood Securities has the Company planning forward for a bright future.

Contact: C.K. Cheung, CEO

EVITRADE Health Systems Corporation
(formerly Auxellence Health Corporation)

Email info@evahealthsystems.com

Website <http://www.evahealthsystems.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>

US OTC Markets: <http://www.otcmarkets.com/stock/AXHLF/news>



**EViTRADE
Health
Systems
Corporation**

About EViTRADE Health (CSE: EVA, OTCQB: AXHLF)

EViTRADE (formerly Auxellence Health Corp.), was founded in 2013 to provide online “digital healthcare” services for resolving common health problems. The current markets are weight-management, high blood pressure, high blood glucose and heart arrhythmia.

Disclaimers – Forward Looking Statements

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>, and <http://www.otcmarkets.com/stock/AXHLF/filings>. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.